On August 9, 2020, the SEC filed a complaint against Adaptimmune Therapeutics, Inc. (NASDAQ:ADAP), alleging that it failed to develop a treatment for ovarian cancer.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, alleges that the company failed to develop a treatment for ovarian cancer. The SEC's complaint, filed in the SEC's Eastern District of New York, alleges that the company did not develop a treatment for ovarian cancer. The complaint further alleges that the company failed to develop a companion diagnostic for ovarian cancer. The SEC's complaint, which was filed in the U.S. District Court, alleges that the company failed to develop a diagnostic for ovarian cancer. The SEC's complaint charges that the company failed to develop a companion diagnostic, and that it was not developed. The SEC's complaint charges that the company violated Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder. Without admitting or denying the allegations in the SEC's complaint, Adaptimmune has agreed to the entry of a final judgment that permanently enjoins it from violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Donna Lunger with the assistance of Marc Frahm of the Cowen and Company unit. The litigation will be led by Ms. Lunger. The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.